If You Are Living With HIV
If you are living with HIV, you may be eligible to participate in one of our clinical trials. Please click the links below if you would like more information about our open trials. If you are interested in participating, please contact Melissa La Mar at 212-327-7280 or e-mail her at mlamar@adarc.org.Clinical Trials for Patients Living with HIV
(MMA-0591)
HIV Elite Controller Study
HIV Elite Controller Study
The focus of the studies to be conducted under this protocol and consent form is on the detailed analysis of host cellular and humoral immune responses, comprehensive human genome analysis and genomic analysis of the infecting viruses isolated from persons that control HIV Infection.
(MMA-0728)
A Phase 3, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy
A Phase 3, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy
The reason for doing this research is to find out if an investigational drug called GSK1349572 can help people with HIV. The purpose of this study is to test the safety of GSK1349572 and how well it works.
(MMA-0754)
Viral and Host factors in the transmission and pathogenesis of HIV
Viral and Host factors in the transmission and pathogenesis of HIV
A Phase 2b Randomized, Double-Blind, Double-Dummy Trial of Once-Daily Doses of Cenicriviroc or Once-Daily EFV, Each with Open-Label FTC/TDF, in HIV-1-Infected, Antiretroviral Treatment-Naïve, Adult Patients
(MMA-0761)
A Phase 3b Randomized, Open-Label Study in Virologically-Suppressed, HIV-1 Infected Patients (GS-US 236-0121)
A Phase 3b Randomized, Open-Label Study in Virologically-Suppressed, HIV-1 Infected Patients (GS-US 236-0121)
The purpose of this study is to see if HIV-infected subjects currently taking an antiretroviral (ARV) regimen consisting of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) plus FTC/TDF (Truvada®) can safely switch to EVG/COBI/FTC/TDF STR without increasing the amount of virus in their blood.
(MMA-0781)
A Phase IIb, dose ranging study of oral GSK1265744 in combination with nucleoside reverse transcriptase inhibitors
A Phase IIb, dose ranging study of oral GSK1265744 in combination with nucleoside reverse transcriptase inhibitors
The purpose of this study is to test the safety of GSK1265744 and how well it works. Three different doses of GSK1265744 will be compared in order to choose the best dose. About 200 people in the United States will take part in this study.